Jupiter Neurosciences Expands Brain Health Reach with Nugevia Supplement Line

Jupiter Neurosciences Inc. (NASDAQ: JUNS) is expanding its brain health expertise beyond pharmaceutical development with the launch of Nugevia, a direct-to-consumer longevity product line aimed at improving mitochondrial support, mental clarity and beauty from within. The clinical-stage pharmaceutical company, known for developing JOTROL, an enhanced orally administered resveratrol formulation, expects its Nugevia MND cognitive health supplement to account for about 60% of company sales by volume.

The global brain health supplement market is projected to reach approximately $23 billion by 2030, growing at a compound annual growth rate of around 13% between now and then. This growth is driven by aging populations worldwide seeking to maintain mental clarity, focus and resilience as they live longer. Brain health has become central to quality of life considerations as people recognize that cognitive vitality drives every aspect of performance from memory to motivation.

Jupiter Neurosciences brings pharmaceutical credibility to the supplement space through its Nugevia MND formulation, which builds directly on the company's clinical research in neuroinflammation and central nervous system function. The company's spokesperson noted that consumer awareness in brain health is accelerating rapidly, making this the most natural bridge between their clinical work and consumer wellness offerings. The formulation addresses neuroinflammation, mitochondrial health and cellular protection - the same biological pathways that define both aging and cognition.

All Nugevia products are derived from JOTROL, the company's first-in-class oral therapeutic designed to deliver therapeutically relevant, safe levels of resveratrol. While resveratrol has been available for years, Jupiter Neurosciences overcame previous limitations by developing a delivery system that provides about nine times higher absorption and proven central nervous system penetration. Beyond its antioxidant and anti-inflammatory effects, resveratrol activates PARP-1, an important protein in DNA repair and stress response, while also improving cardiovascular health, enhancing cognitive function, and providing antibacterial and antiviral properties against food-borne pathogens.

Phase one trials determined JOTROL was safe and well-tolerated at all dose levels, demonstrating blood plasma levels 8-10-fold higher than naïve resveratrol administered in historical clinical trials. The phase two trial focuses on treating Alzheimer's, Parkinson's and a broad spectrum of CNS and rare diseases. JOTROL has patents in the U.S., Europe, China, Hong Kong and Japan protected through 2036.

What sets Nugevia apart from single-ingredient supplements is its precision-engineered intelligent stacking of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery and promote system-wide optimization. The company has garnered support from multiple scientists and brand ambassadors including former tennis great Annika Sörenstam, NBA legend Chris Webber, scientist Charbel Moussa and biohacker Jean Fallacar, who represent different audiences from elite athletes to entrepreneurs.

The company emphasizes that its entry into supplements comes from clinical expertise rather than marketing, representing a natural evolution of its dual-path strategy: advancing prescription therapies for patients while empowering everyday consumers with credible, evidence-based solutions for healthy aging. This approach positions Jupiter Neurosciences uniquely in the rapidly expanding brain health market as consumers increasingly seek scientifically validated cognitive support products.